Illumina, Inc. (NASDAQ:ILMN) EVP Marc Stapley Sells 2,000 Shares
Illumina, Inc. (NASDAQ:ILMN) EVP Marc Stapley sold 2,000 shares of the firm’s stock in a transaction dated Friday, July 14th. The shares were sold at an average price of $173.56, for a total transaction of $347,120.00. Following the completion of the transaction, the executive vice president now directly owns 39,941 shares in the company, valued at $6,932,159.96. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Marc Stapley also recently made the following trade(s):
- On Monday, June 12th, Marc Stapley sold 2,000 shares of Illumina stock. The shares were sold at an average price of $170.85, for a total transaction of $341,700.00.
Illumina, Inc. (ILMN) traded down 0.34% on Monday, hitting $171.74. 1,126,873 shares of the company were exchanged. The company has a market capitalization of $25.07 billion, a price-to-earnings ratio of 34.76 and a beta of 0.84. The stock has a 50 day moving average of $177.31 and a 200 day moving average of $165.72. Illumina, Inc. has a 52 week low of $119.37 and a 52 week high of $189.48.
Illumina (NASDAQ:ILMN) last issued its earnings results on Tuesday, April 25th. The life sciences company reported $0.64 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.64. Illumina had a net margin of 30.75% and a return on equity of 21.21%. The firm had revenue of $598 million for the quarter, compared to analysts’ expectations of $590.51 million. During the same quarter last year, the business earned $0.71 earnings per share. The business’s revenue was up 4.5% on a year-over-year basis. Analysts predict that Illumina, Inc. will post $3.63 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This piece was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another site, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/07/17/illumina-inc-nasdaqilmn-evp-marc-stapley-sells-2000-shares.html.
Several hedge funds and other institutional investors have recently modified their holdings of ILMN. Advocacy Wealth Management Services LLC acquired a new stake in shares of Illumina during the first quarter worth approximately $102,000. Advisory Services Network LLC acquired a new stake in shares of Illumina during the first quarter worth approximately $117,000. Gemmer Asset Management LLC raised its stake in shares of Illumina by 5.7% in the first quarter. Gemmer Asset Management LLC now owns 686 shares of the life sciences company’s stock worth $117,000 after buying an additional 37 shares during the last quarter. Patten Group Inc. raised its stake in shares of Illumina by 2.7% in the first quarter. Patten Group Inc. now owns 965 shares of the life sciences company’s stock worth $166,000 after buying an additional 25 shares during the last quarter. Finally, NN Investment Partners Holdings N.V. raised its stake in shares of Illumina by 11.3% in the second quarter. NN Investment Partners Holdings N.V. now owns 985 shares of the life sciences company’s stock worth $171,000 after buying an additional 100 shares during the last quarter. Hedge funds and other institutional investors own 93.73% of the company’s stock.
ILMN has been the topic of several recent analyst reports. Piper Jaffray Companies reissued an “overweight” rating and issued a $187.00 target price (up from $170.00) on shares of Illumina in a report on Friday, April 14th. Vetr lowered shares of Illumina from a “strong-buy” rating to a “buy” rating and set a $197.84 price target on the stock. in a report on Wednesday, June 21st. TheStreet raised shares of Illumina from a “c+” rating to a “b” rating in a report on Thursday, April 6th. BTIG Research reaffirmed a “hold” rating on shares of Illumina in a report on Sunday, March 19th. Finally, Cowen and Company reaffirmed an “outperform” rating and set a $200.00 price target on shares of Illumina in a report on Wednesday, April 26th. Four equities research analysts have rated the stock with a sell rating, ten have given a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $166.30.
Illumina Company Profile
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.